PS1-20: Hospice Use in Metastatic Colorectal Cancer Patients

Background/Aims Colorectal cancer is the third most common cancer diagnosis in the US, with a lifetime risk of 5.1%. It is the second leading cause of cancer death, and is predicted to cause approximately 50,000 deaths in 2011. With a five year survival rate of less than 25%, the majority of patients diagnosed with metastatic colorectal cancer face decisions about end of life care. This study seeks to understand what influences hospice utilization among metastatic colorectal cancer patients who are part of the Comparative Effectiveness in Genomics and Personalized Medicine for Colon Cancer (CERGEN) population.